Prognostic Value of Osteoprotegerin in Acute Heart Failure

Canadian Journal of Cardiology

Volumn 31, Issue 10, 2015, Pages 1266-1271

  Friões, Fernando ^a,b   Laszczynska, Olga ^c   Almeida, Pedro Bernardo ^a   Silva, Nuno ^a   Guimarães, João Tiago ^a,b,c   Omland, Torbjørn ^d,e   Azevedo, Ana ^b,c   Bettencourt, Paulo ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OSTEOPROTEGERIN; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PORTUGAL; PROGNOSIS; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; ACUTE DISEASE; BLOOD; COHORT ANALYSIS; EPIDEMIOLOGY; HEART FAILURE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL;

ACUTE DISEASE; AGED; BIOMARKERS; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; PORTUGAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84942367694     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.04.003     Document Type: Article

References (43)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
2. Kiechl S., Werner P., Knoflach M., et al. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006, 4:801-811.
3. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
4. Sandberg W.J., Yndestad A., Øie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26:857-863.
5. Kalaycioğlu E., Gökdeniz T., Aykan A.Ç., et al. Osteoprotegerin is associated with subclinical left ventricular systolic dysfunction in diabetic hypertensive patients: a speckle tracking study. Can J Cardiol 2014, 30:1529-1534.
6. Crisafulli A., Micari A., Altavilla D., et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005, 109:389-395.
7. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
8. Lindberg S., Jensen J.S., Hoffmann S., et al. Osteoprotegerin levels change during STEMI and reflect cardiac function. Can J Cardiol 2014, 30:1523-1528.
9. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
10. Lieb W., Gona P., Larson M.G., et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010, 30:1849-1854.
11. Pedersen S., Mogelvang R., Bjerre M., et al. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012, 123:31-38.
12. Ware C.F. The TNF superfamily. Cytokine Growth Factor Rev 2003, 14:181-184.
13. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
14. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
15. Kelly R.A., Smith T.W. Cytokines and cardiac contractile function. Circulation 1997, 18(95):778-781.
16. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
17. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
18. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
19. Liu W., Feng W., Wang F., et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodelling due to immune-inflammatory myocardial disease. Exp Mol Pathol 2008, 84:213-217.
20. Ueland T., Yndestad A., Øie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005, 111:2461-2468.
21. Putko B.N., Yogasundaram H., Oudit G.Y. Cardiovascular pathophysiology: is it a tumour necrosis factor superfamily affair?. Can J Cardiol 2014, 30:1492-1495.
22. Røysland R., Masson S., Omland T., et al. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J 2010, 160:286-293.
23. Ueland T., Dahl C.P., Kjekshus J., et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011, 4:145-152.
24. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
25. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-215.
26. Maggioni A.P., Dahlström U., Filippatos G., et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010, 12:1076-1084.
27. Damasceno A., Mayosi B.M., Sani M., et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the Sub-Saharan Africa Survey of Heart Failure. Arch Intern Med 2012, 172:1386-1394.
28. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-292.
29. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
30. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27:2725-2736.
31. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
32. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
33. Siirila-Waris K., Lassus J., Melin J., et al. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006, 27:3011-3017.
34. Maggioni A.P., Dahlström U., Filippatos G., et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013, 15:808-817.
35. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
36. Nitta K., Akiba T., Uchida K., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003, 42:303-309.
37. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
38. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
39. Braunwald E. Heart failure. JACC Heart Fail 2013, 1:1-20.
40. Aramburu-Bodas O., García-Casado B., Salamanca-Bautista P., et al. Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction. J Cardiovasc Med (Hagerstown) 2015, 16:438-443.
41. Ueland T., Yndestad A., Dahl C.P., Gullestad L., Aukrust P. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep 2012, 9:92-100.
42. Leder B.Z., Tsai J.N., Uihlein A.V., et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 2014, 99:1694-1700.
43. Rolfo C., Raez L.E., Russo A., et al. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opin Biol Ther 2014, 14:15-26.